The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites
Increased insulin production can help lower blood sugar levels and counteract insulin resistance, which may help with weight loss
Macrogol is an osmotic laxative that draws water into the bowel to soften stools and is recommended by NICE as first-line treatment for chronic constipation in adults Constipation affects 1-10% of Ozempic users and over 10% of Wegovy users, caused by semaglutide's effect on gastrointestinal motility Bulk-forming laxatives like ispaghula husk may suit mild constipation but require adequate fluid intake to prevent obstruction Stimulant laxatives such as senna or bisacodyl provide short-term relief for severe constipation and should be used under medical supervision No specific laxative interactions with Ozempic are documented, but patients should inform healthcare providers of all medications taken Persistent or severe constipation, abdominal pain, vomiting, or inability to pass stool requires urgent medical assessment Not sure where to start
TrimRx offers flexible pricing for Dallas patients
Theyre designed to help people lose and keep off weight
October 19, 2024 A Louisiana plaintiff from DeRidder has filed a lawsuit citing severe health complications allegedly caused by Ozempic, including gastroparesis leading to stomach paralysis
